Bio-Path Hldgs Inc Stock Price, News & Analysis

Bio-Path Holdings Update on Clinical Milestones

HOUSTON, March 16, 2023 – Bio-Path Holdings (NASDAQ: BPTH) provided a clinical update on its DNAbilize® liposomal technology targeting cancer treatments. In 2022, the company advanced its clinical trials, expecting significant milestones in 2023. Key trials include: BP1001-A for solid tumors, with data expected mid-year; BP1002 for AML, with results anticipated in Q2 2023; and a Phase 2 trial for prexigebersen in AML, showing promising early efficacy. The company also expanded its manufacturing capacity and intellectual property portfolio, crucial for future development.

Bio-Path Holdings (NASDAQ:BPTH) announced the successful enrollment and dosing of the first patient in its Phase 1/1b clinical trial for BP1001-A, targeting solid tumors such as ovarian, endometrial, pancreatic, and breast cancer. This advancement reflects the potential of BP1001-A, a modified version of prexigebersen, to provide effective treatment options for patients with limited options. The trial aims to evaluate safety and efficacy at major cancer centers, with expected insights into BP1001-A's effectiveness.

Bio-Path Holdings (NASDAQ: BPTH) announced Q3 2022 financial results, reporting a net loss of $3.5 million or $0.49 per share, compared to a net loss of $2.1 million or $0.29 per share in Q3 2021. Research and development expenses rose to $2.4 million due to manufacturing costs and clinical trial startup expenses. As of September 30, 2022, the company had $13.7 million in cash, down from $23.8 million at year-end 2021. Notably, Bio-Path initiated a Phase 1/1b study for BP1002 in acute myeloid leukemia and closed a $2 million offering in November.

Bio-Path Holdings, Inc. (NASDAQ: BPTH) will host a live conference call on November 15, 2022, at 8:30 a.m. ET to report third-quarter financial results ending September 30, 2022. The call will provide a business overview and is accessible via phone or webcast. Bio-Path is recognized for its DNAbilize® technology, fostering a pipeline of targeted RNAi nanoparticle drugs. Key products include prexigebersen and BP1002, aimed at treating blood cancers and solid tumors. An IND for BP1003 is anticipated to be filed by early 2023.

Bio-Path Holdings, Inc. (NASDAQ: BPTH) has announced a registered direct offering of 800,000 shares of common stock at $2.50 per share, aiming for gross proceeds of approximately $2 million. In a concurrent private placement, the company will issue unregistered warrants to purchase up to 800,000 shares at an exercise price of $2.85 per share. The offerings are expected to close around November 9, 2022. Proceeds will be allocated for working capital and general corporate purposes, bolstering their development of targeted nucleic acid cancer drugs using the DNAbilize technology.

Bio-Path Holdings announced the first patient enrollment in a Phase 1/1b clinical trial for BP1002, targeting venetoclax-resistant acute myeloid leukemia (AML) patients. This trial aims to assess BP1002's ability to inhibit Bcl-2 protein, which is linked to poor prognosis in AML. The trial includes notable cancer centers and plans to evaluate BP1002 in combination with decitabine after initial monotherapy. The outcome of this trial could significantly impact treatment options for patients with limited life expectancy.

Bio-Path Holdings, a biotechnology firm focused on developing targeted nucleic acid cancer drugs, announced that CEO Peter Nielsen will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. The presentation will be available as a pre-recorded audio webcast starting at 7:00 a.m. ET and can be accessed on the company's website. Bio-Path's lead candidate, prexigebersen, is in a Phase 2 trial for blood cancers, while other products are in various stages of development, aiming to target specific cancer proteins.

Bio-Path Holdings, Inc. (NASDAQ:BPTH) reported its financial results for Q2 2022, posting a net loss of $3.0 million or $0.42 per share, up from a net loss of $1.8 million in Q2 2021. Research and development expenses grew to $1.9 million due to increased clinical trial activities. Cash reserves decreased to $17.0 million as of June 30, 2022. The company anticipates commencing Phase 1 studies for BP1001-A and BP1002 shortly and presented encouraging preclinical data for BP1003 at the AACR Annual Meeting.

Bio-Path Holdings (NASDAQ: BPTH) will host a live conference call on August 16, 2022, at 8:30 a.m. ET to discuss its Q2 financial results and provide a business overview. The call can be accessed by calling (833) 630-1956 domestically or (412) 317-1837 internationally. Additionally, a live audio webcast will be available on the company's website, with an archived version posted two hours afterward. Bio-Path is focused on developing DNAbilize^®, a proprietary RNAi nanoparticle technology, targeting cancer therapies.